Nanjing Techdra Medicine

Techdra Medicine is a clinical-stage biopharmaceutical company headquartered in Nanjing, China, specializing in the discovery and development of innovative small molecule drugs. The company focuses on challenging targets, particularly protein-protein interactions (PPI), utilizing a proprietary structure-based drug design (SBDD) and fragment-based drug discovery (FBDD) platform. Its lead program, TD-001, is a potent and selective Menin-MLL inhibitor currently in Phase 1 clinical trials for the treatment of acute leukemias, including acute myeloid leukemia (AML). Techdra aims to address significant unmet medical needs in oncology and immunology through its pipeline of first-in-class and best-in-class therapies. The company is supported by leading venture capital firms and maintains a strong R&D presence in the Nanjing Jiangbei New Area.